Algernon Pharmaceuticals Inc.
Other OTCTotal Valuation
Algernon Pharmaceuticals Inc. carries a market capitalization of 1.10M, placing it among publicly traded companies globally.
| Market Cap | 1.10M |
| Enterprise Value | N/A |
Share Statistics
Algernon Pharmaceuticals Inc. currently has 5.42M shares outstanding.
| Shares Outstanding | 5.42M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 5.74 |
| P/TBV Ratio | -0.34 |
| P/FCF Ratio | -0.57 |
| P/OCF Ratio | -0.57 |
Financial Position
Algernon Pharmaceuticals Inc. maintains a current ratio of 0.25, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.25 |
| Quick Ratio | 0.09 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -139,134.79 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -47.90 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Algernon Pharmaceuticals Inc.'s stock has declined approximately -35.43469% over the past 52 weeks. The 50-day moving average sits at 0.31, while the 200-day moving average is 0.41.
| Beta (5Y) | N/A |
| 52-Week Price Change | -35.43469% |
| 50-Day Moving Average | 0.31 |
| 200-Day Moving Average | 0.41 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -1.95M, while operating income came in at -2.06M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -2.06M |
| Pretax Income | -2.06M |
| Net Income | -2.06M |
| EBITDA | -1.95M |
| EBIT | -2.06M |
| Earnings Per Share (EPS) | -0.90 |
Balance Sheet
Total book value stands at 147,415.00, with working capital of -1.86M providing operational flexibility.
| Cash & Cash Equivalents | 195,349.00 |
| Total Debt | N/A |
| Net Debt | -195,349.00 |
| Equity (Book Value) | 147,415.00 |
| Book Value Per Share | 0.06 |
| Working Capital | -1.86M |
Cash Flow
Algernon Pharmaceuticals Inc. produced -1.49M in operating cash flow over the past twelve months. After subtracting -9,747.00 in capital expenditures, free cash flow totaled -1.50M - equivalent to -0.65 per share.
| Operating Cash Flow | -1.49M |
| Capital Expenditures | -9,747.00 |
| Free Cash Flow | -1.50M |
| FCF Per Share | -0.65 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -170.56 |
| FCF Yield | -174.41 |
Stock Splits
Algernon Pharmaceuticals Inc.'s most recent stock split took place on April 21, 2026 with a 10:1 split ratio.
| Last Split Date | 4/21/2026 |
| Split Ratio | 10:1 |
Scores
Algernon Pharmaceuticals Inc. posts an Altman Z-Score of -79.65, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -79.65 |